Oric Pharmaceuticals (ORIC) Stock Research

Today

Oric Pharmaceuticals reports Q2 EPS (38c), consensus (36c)

ORIC

4:37 PM

Over a week ago

Oric Pharmaceuticals initiates Himalayas-1 trial

Jul 14, 4:06 PM

Oric Pharmaceuticals resumed with a Buy at Stifel

ORIC

Jun 11, 4:13 PM

Oric Pharmaceuticals moved to Buy rating at Goldman Sachs

ORIC

May 15, 5:09 AM

Oric Pharmaceuticals price target lowered by $1 at Citi

ORIC

May 5, 6:32 AM

Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)

ORIC

May 4, 4:36 PM

Oric Pharmaceuticals presents Rinzimetostat preclinical data at AACR

ORIC

Apr 17, 4:10 PM

Oric selloff brings attractive entry point, says H.C. Wainwright

ORIC

Apr 2, 6:11 AM

What You Missed On Wall Street On Wednesday

+27

Apr 1, 4:23 PM

Oric Pharmaceuticals should be bought on selloff, says Citi

ORIC

Apr 1, 1:30 PM

Midday Fly By: Nike falls after earnings, Conagra reports mixed results

+25

Apr 1, 12:12 PM

Oric Pharmaceuticals price target lowered by $3 at Wedbush, here's why

Apr 1, 10:06 AM

Oric's rinzi efficacy 'comparable' to Pfizer's mevro, says Cantor Fitzgerald

Apr 1, 9:36 AM

Oric selloff on cancer data 'appears exaggerated,' says JonesResearch

ORIC

Apr 1, 9:24 AM

Video: Nike stumbles as timeline for recovery pushed out

Apr 1, 8:49 AM

Closing Bell Movers: Nike slides 9% after Q3 results, soft outlook

Mar 31, 7:05 PM

Oric Pharmaceuticals announces rinzimetostat, ORIC-944, program update

ORIC

Mar 31, 6:34 PM

Oric selloff brings favorable entry point, says H.C. Wainwright

ORIC

Mar 13, 6:11 AM

Oric Pharmaceuticals reports Q4 revenue C$17.39M vs. C$18.04M last year

ORIC

Mar 12, 7:49 AM

Oric Pharmaceuticals selloff a buying opportunity, says JPMorgan

ORIC

Mar 10, 6:30 AM

What You Missed On Wall Street On Monday

+39

Mar 9, 4:13 PM

Cantor says Oric move down on tazemetostat withdrawal an 'over-reaction'

Mar 9, 1:43 PM

Midday Fly By: Hims & Hers reaches Novo deal, Live Nation settles with DOJ

+30

Mar 9, 12:02 PM

Oric Pharmaceuticals falls after peer Ipsen voluntarily withdraws Tazverik

Mar 9, 10:59 AM

Oric Pharmaceuticals price target raised by $2 at H.C. Wainwright, here's why

ORIC

Feb 24, 10:50 AM

Specialized Focus on Overcoming Drug Resistance in Oncology: Oric's core strategy centers on developing therapies that circumvent or overcome the mechanisms by which cancer cells develop resistance to existing treatments, addressing a critical unmet need in oncology.

Diversified Pipeline Targeting Multiple Resistance Pathways: The company boasts a pipeline with several distinct programs (e.g., ORIC-114, ORIC-533, ORIC-944) each employing a different mechanism of action to tackle various forms of cancer drug resistance, spreading scientific and development risk.

Strategic Collaboration with Pharma Partner: Oric has established a partnership with Pfizer for its CD73 inhibitor ORIC-533, providing external validation, potential resources, and shared development expertise for one of its key assets.

Clinical Trial Outcomes Risk: Oric's drug candidates, including ORIC-114, ORIC-533, and ORIC-944, may fail to demonstrate efficacy or an acceptable safety profile in ongoing or future clinical trials, leading to termination of development and significant financial loss.

Regulatory Approval Uncertainty Risk: Oric Pharmaceuticals may not obtain the necessary regulatory approvals from agencies like the FDA or EMA for its drug candidates, which could be due to insufficient data, unexpected side effects, or changes in regulatory requirements, preventing market access.

Intense Competition Risk: The oncology therapeutic area is highly competitive, and Oric's drug candidates may not achieve significant market share or may be rendered obsolete by competing therapies from larger, more established pharmaceutical companies.